InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLF
Post# of 229
(Total Views: 1123)
Posted On: 09/27/2017 6:09:35 PM
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies
- Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids
- Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases
- Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder
Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has no approved treatments, according to the Dystrophic Epidermolysis Bullosa Research Association of America. Researchers at InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), however, hope to treat this unmet medical need with a topical drug called INM-750 that includes multiple biosynthesized cannabinoids as its active ingredients.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases. The company’s biosynthesis platform works by inserting the plant’s DNA into E. coli bacteria that has the internal ability to manufacture specific cannabinoid compounds.
Couple this approach with a proprietary bioinformatics data assessment tool created by InMed Pharmaceuticals, and the possibilities are endless. In its corporate presentation, the company details the potential benefits of biosynthesis of cannabinoids as wide-ranging, noting that the procedure could enable enhanced quality control and purification while unlocking the minor cannabinoids that are currently too difficult and expensive to produce and study (http://nnw.fm/d7MHp).
Glaucoma, one of the world’s leading causes of blindness, is another life-changing disease that InMed’s proprietary research is zeroing in on. InMed’s INM-085 biosynthesized, topical glaucoma treatment will be the first of its kind – utilizing numerous cannabinoids for optimal efficacy as it treats the affected eye’s cells and optic nerve tissues. The company projects the potential revenue for these two drugs alone at $6 billion a year (http://nnw.fm/L32rz).
But there are other, equally devastating diseases that InMed Pharmaceutical researchers propose targeting in their quest to biosynthesize therapeutic drugs from cannabis and other botanical sources. Rheumatoid arthritis, epilepsy, asthma and diabetes are some of the more well-known names. The benefits of using InMed’s proprietary biosynthesis procedure to manufacture any of the 90-plus identified cannabinoids in marijuana reads like a wish list for investors:
There are significant cost savings versus the traditional method of growing thousands of plants and then extracting cannabinoids
Quality control, which includes enhanced production and purification, means a superior, standardized product
InMed’s comprehensive database uses a bioinformatics platform to select specific cannabinoid combinations that may help treat targeted diseases
Preclinical formulation of therapy drugs this year will lead to expected clinical trials in 2018
Leading research estimates set the 2016 legal cannabis market in North America anywhere from $6.7 billion to $7.2 billion. Growth projections are also “off the charts,” as a stunning compound annual sales growth rate of 25 percent is expected through 2021, and a $50 billion global market is considered possible by 2025 (http://nnw.fm/l0EKZ).
Looking ahead, InMed Pharmaceuticals President and CEO Eric A. Adams said he believes the company’s technology will have a huge impact on the booming cannabis industry.
“When I saw the technology that InMed has, I knew right away that it was going to be something big,” Adams said in a recent interview published in MERRY JANE, an online resource for news, culture and video covering cannabis. “The science behind the company is a real game changer (http://nnw.fm/O3ptU).”
In a move to strengthen the company’s core, InMed has also retained the consulting services of Ben Paterson, P.E., who will assist in defining the pathway for the scale-up, purification and manufacturing strategies for the company’s cannabinoid biosynthesis program. Patterson is a principal consultant at PatersonChemE Consulting, LLC.
Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He previously spent 37 years with Eli Lilly and Company as a senior engineering advisor, including 24 years in the biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale.
“Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Adams said in a news release announcing Paterson’s appointment (http://nnw.fm/0jdLo). “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids
- Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases
- Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder
Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has no approved treatments, according to the Dystrophic Epidermolysis Bullosa Research Association of America. Researchers at InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), however, hope to treat this unmet medical need with a topical drug called INM-750 that includes multiple biosynthesized cannabinoids as its active ingredients.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases. The company’s biosynthesis platform works by inserting the plant’s DNA into E. coli bacteria that has the internal ability to manufacture specific cannabinoid compounds.
Couple this approach with a proprietary bioinformatics data assessment tool created by InMed Pharmaceuticals, and the possibilities are endless. In its corporate presentation, the company details the potential benefits of biosynthesis of cannabinoids as wide-ranging, noting that the procedure could enable enhanced quality control and purification while unlocking the minor cannabinoids that are currently too difficult and expensive to produce and study (http://nnw.fm/d7MHp).
Glaucoma, one of the world’s leading causes of blindness, is another life-changing disease that InMed’s proprietary research is zeroing in on. InMed’s INM-085 biosynthesized, topical glaucoma treatment will be the first of its kind – utilizing numerous cannabinoids for optimal efficacy as it treats the affected eye’s cells and optic nerve tissues. The company projects the potential revenue for these two drugs alone at $6 billion a year (http://nnw.fm/L32rz).
But there are other, equally devastating diseases that InMed Pharmaceutical researchers propose targeting in their quest to biosynthesize therapeutic drugs from cannabis and other botanical sources. Rheumatoid arthritis, epilepsy, asthma and diabetes are some of the more well-known names. The benefits of using InMed’s proprietary biosynthesis procedure to manufacture any of the 90-plus identified cannabinoids in marijuana reads like a wish list for investors:
There are significant cost savings versus the traditional method of growing thousands of plants and then extracting cannabinoids
Quality control, which includes enhanced production and purification, means a superior, standardized product
InMed’s comprehensive database uses a bioinformatics platform to select specific cannabinoid combinations that may help treat targeted diseases
Preclinical formulation of therapy drugs this year will lead to expected clinical trials in 2018
Leading research estimates set the 2016 legal cannabis market in North America anywhere from $6.7 billion to $7.2 billion. Growth projections are also “off the charts,” as a stunning compound annual sales growth rate of 25 percent is expected through 2021, and a $50 billion global market is considered possible by 2025 (http://nnw.fm/l0EKZ).
Looking ahead, InMed Pharmaceuticals President and CEO Eric A. Adams said he believes the company’s technology will have a huge impact on the booming cannabis industry.
“When I saw the technology that InMed has, I knew right away that it was going to be something big,” Adams said in a recent interview published in MERRY JANE, an online resource for news, culture and video covering cannabis. “The science behind the company is a real game changer (http://nnw.fm/O3ptU).”
In a move to strengthen the company’s core, InMed has also retained the consulting services of Ben Paterson, P.E., who will assist in defining the pathway for the scale-up, purification and manufacturing strategies for the company’s cannabinoid biosynthesis program. Patterson is a principal consultant at PatersonChemE Consulting, LLC.
Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He previously spent 37 years with Eli Lilly and Company as a senior engineering advisor, including 24 years in the biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale.
“Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Adams said in a news release announcing Paterson’s appointment (http://nnw.fm/0jdLo). “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)